



ДЕРМАТОВЕНЕРОЛОГИЯ И ЭСТЕТИЧЕСКАЯ МЕДИЦИНА CLINICAL AND AESTHETIC DERMATOLOGY

УДК 615.03-616-053.2

Sarnai Sukhbaatar¹, Enkhtur Yadamsuren², Sarantuya Jav³, Narantungalag Dorjsuren¹

¹Department of Pharmacology, School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaabaatar, Mongolia;

²Department of Dermatology, School of Medicine, Mongolian National University of Medical Sciences, Ulaabaatar, Mongolia;

³Department of Molecular Biology and Genetics, School of Bio-Medicine, Mongolian National University of Medical Sciences, Ulaabaatar, Mongolia

CUTANEOUS ADVERSE DRUG REACTIONS IN MONGOLIAN PEDIATRIC PATIENTS

Cutaneous adverse drug reactions (CADRs) are rare and tend to increase in recent years. The aim of the study is to reveal the medicines affecting the development of drug-related skin disorders. We analyzed pediatric data in the National Dermatology Center of Mongolia, which was built retrospectively in 2019 with CADRs cases treated in that hospital during 2013-2018. 204 pediatric patients CADRs cases were included. The common offending drug groups were antimicrobials (50.4%), anti-inflammatory drugs (28%) and antiepileptic drugs (1.47%). The incidence of cutaneous adverse reactions to drugs is higher in male than female.

Among the inpatients of National Dermatology Center of Mongolia, drugs that cause major skin disorders affect the antibacterial and nervous system. Usually toddlers more than adolescents affected by the drug related skin disorders.

Keywords: adverse drug reaction, skin disorders, children

Introduction: CADRs are problem of global health. The World Health Organization (WHO) ¹ defines an adverse drug reaction (ADR) as “any response to a drug which is noxious and unintended, and which occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for the modification of physiologic function”.

Although the leading causes of population morbidity are stratified by location, diseases of the respiratory, digestive and cardiovascular systems are the three leading causes both in urban and rural areas². Therefore, drug consumption are increasing every year. Drug induced skin disorders (DISD) such as allergic contact dermatitis (L23), dermatitis due to substances taken internally (L27), urticaria (L50), erythema multiform, Stevens-Johnson syndrome, toxic epidermal necrolysis (L51) and erythema nodosum (L52) are included in International Classification of Diseases – 10 revision (ICD-10) ³ are caused by irrational use of medicines are increasing in population. Irrational use of medicines is an extremely serious global problem that is wasteful and harmful. In developing and transitional countries, in primary care less than 40% of patients in the public sector and 30% of patients in the private sector are treated in accordance with standard treatment guidelines⁴.

Cutaneous adverse drug reactions (CADRs) are most commonly associated with antimicrobial agents (AA), non steroidal anti-inflammatory drugs (NSAID) and anti-epileptic drugs (AED)⁶ which are included “8th Essential drug list” of the Mongolia. In the Mongolia AA and AED are written by doctors on the prescription and NSAID can sold with or without prescription. Parliament of Mongolians decision №57 09th October, 2014 detailed and again declared that antibiotics should prescribed⁵.

CADRs are one of the most common types of adverse drug reactions⁶. Incidence and severity of CADRs are increasing last years. Many factors particularly drugs consumption, age, sex are affecting CADRs.

The aim of the study is to reveal the medicines affecting the development of drug-related skin disorders.

Materials and Method: The NDCM is located in the capital city of Mongolia which specialized only tertiary teaching hospital can serve who is suffering from cutaneous adverse drug reactions. Medical histories were collected and archived between 2013 and 2018 in the archives of the NDCM. We conducted a study on the medical histories of 31,993 patients (adult and child), who were hospitalized at NDCM from 2013 to 2018.

In this retrospective study, we used medical histories with L23, L27, L50-52 diagnosis that are causes by any medication. Patients are included who used of prescription or non-prescription medication, CADRs are developed and those cases should require special medical care. The diagnosis of the CADRs was done by the dermatologists who are working in the NDCM. In patient with incomplete history were excluded in this study. All the patients were given adequate treatment (soothing lotions, local / oral antibiotics or steroids, antihistamines) depending upon the severity of CADRs.

Data about age, gender, diagnosis, treatment were retrospectively collected from patients' medical history.

Statistical analysis

Descriptive statistics was used for data analysis and results were expressed as percentages.

Ethical statements

Prior to beginning the study, the study design and ethics were approved by Ethical Review Committee of Mongolian National University of Medical Sciences (№2018/3-10, 08 June 2017).

Results: 1. Baseline characteristics

CADRs are possible for any age and included from 2 months to 18 years old. The mean age of diagnosis was 5.89 ± 5.28 years old. Of the total 204 cases selected, 76 (37.3%) were females and 128 (62.7%) were males. The male to female ratio was 0.59:1.68.

Of the total 924 pediatric patients who is treated for those diagnosis in the last five years. Of them 204 (22.07%)



CADR were caused by drug consumption. The remaining over 78% was caused by food and chemical substances.

L27 was the most common diagnosis (n=115) 62.5%, followed by L50 (n=62) 24.5%, L51 (n=18) 8.38%, L23 (n=5) 2.5%, L52 (n=4) 1.9% (Table 1).

Table1 - CADRs amount between 2013 and 2018

	L50	L51	L52	L23	L27	Total
2013	4	2		1	19	26
2014	12	2	2	1	28	45
2015	5	3			25	33
2016	4	3	1		5	13
2017	13	3		2	20	38
2018	24	5	1	1	18	49
						204

2. Drugs responsible for CADRs.

Table2 show the drugs most commonly responsible for CADRs were antimicrobial (50.4%), followed by non

steroidal anti-inflammatory drugs (NSAIDs) (28%) and antiepileptic drugs (1.47%).

Table2 - Etiology of pediatric CADRs

Etiology	SJS	Cutaneous findings	
		Rash	Blister
Antibiotics			
Penicillin			
Amoxicillin		42	17
Ampicillin		4	1
Cephalosporine		6	4
Macrolide		15	3
Sulfonamide		9	2
NSAIDS		20	7
Acetaminophen			
Ibuprofen		26	4
Antiepileptic			
Carbamazepine	3		
Other		39	2

The lag period between starting the drug and appearance of cutaneous reactions varied between 30 minutes and a day in maximum number of cases and a case severe CADRs are excluded.

Outcome of CADRs showed all patients cured and improved.

Discussion.

Hea Lin Oh et al study's⁷ sex ratio was same. The study was performed in the Korean Severe CADRs (SCADRs) registry, which was built retrospectively in 2016 with SCADRs cases treated in 34 tertiary referral university hospitals during 2010-2015. They selected 47 SCADRs and 68.1% were male. Deng Q et al⁸ also notified twenty-five studies reported the proportion of men was 53.2%. But other studies' sex ratio was similar such as another study's⁹ reported male were 48.7%.

In this study, CADRs prevalence rate was about 2/1000. Most epidemiological studies analyzed the occurrence of CADRs in inpatients and revealed a wide variation in the prevalence rate which ranged from 0.36% to 12.2%¹⁰. However, some study concluded a prevalence of 3.6/1000 among hospitalized patients was estimated¹¹. On the other hand, incidence of CADRs was not a higher than other countries. These results showed us that we could manage, develop of prevention and provide information to physicians and pharmacists. The top CADRs were rash including non-specified rash, follicular rash, maculopapular rash and vesicular rash¹². The most common reaction was immediate reactions, i.e. urticarial and angioedema contributing over half of cases. Cutaneous clinical manifestations are diverse ranging

from mild or moderate reactions, such as urticarial and maculopapular rash. CADRs are known due to their high morbidity and mortality.

Most studies show that antibiotic, NSAIDS is caused CADRs¹³⁻¹⁴. Usually pediatric and general department use antibiotics widely because there are used for treatment and prophylaxis of various infectious conditions.

Use of multiple drugs is associated with higher incidence of drug reactions as observed with increased frequency in hospitalized patients. In globally, the major causative drug groups were antimicrobials, NSAIDs and anti-epileptic drugs. Therefore those group medicines should be prescribed and monitored specialized physicians. At the same time patients should be sensitized about hazards of self-medications.

Further moreover, we need to detect HLA-B*15:02; HLA-A*31:01 allele was identified as a strong genetic marker for carbamazepin-induced CADRs in Asian population.

Clinicians should carefully evaluate the signs and symptoms of all cutaneous adverse drug reactions thought to be due to drugs and immediately discontinue drugs that are not essential. Short cycles of systemic corticosteroids in combination with antihistamines may be necessary for widespread exanthematous rashes; while more aggressive corticosteroid regimens or intravenous immunoglobulin's associated with supportive treatment should be used for patients with Stevens-Johnson syndrome or toxic epidermal necrolysis¹⁵.

Acknowledgements.



We acknowledge our sincerest gratitude for the staffs of

training service - library of the NDCM.

REFERENCES

- 1 WHO. Safety of medicines. A guide to detecting and reporting adverse drug reactions. 2000. URL: http://archives.who.int/tbs/safety/esd_safety.pdf
- 2 WHO and Center for health development // Health indicators. – 2017. – P. 74-102.
- 3 ДЭМБ, ICD 10, 10th edition
- 4 WHO. World medicines situation Report 20115 WHO, Geneva, Switzerland, 2011.
- 5 Order about legalization of medication of the government of Mongolia №57. URL: <http://apps.who.int/medicinedocs/documents>
- 6 Lucian L.Leape, M.D., Troyen A.Brennan et all. The nature of adverse events in hospitalized patients // The New England Journal of Medicine. – 1991. – Vol.324, №6. – P. 377-384.
- 7 Hea Lin Oh, Dong Yoon Kand, Hye-Ryun Kang et all. Severe cutaneous adverse reactions in Korean pediatric patients: A study from the Korea SCAR Registry // AAIR. – 2019. - №11(2). – P. 241-253.
- 8 Deng Q, Zeng Q, Jing Chen et all. Severe cutaneous adverse drug reactions of Chinese inpatients: a meta-analysis // An Bras Dermatol. – 2017. - №92(3). – P. 345-349.
- 9 Min Gyu Kang, Kyung Hee Sohn, Dong Yoon Kang et all. Analysis of individual case safety reports of severe cutaneous adverse reactions in Korea // YMJ. – 2019. - №60(2). – P. 2018-2215.
- 10 Punit Kumar Singh, Mani Kant Kumar, Dharmendra Kumar and Prashant Kumar. Morphological Pattern of Cutaneous Adverse Drug Reactions due to Antiepileptic Drugs in Eastern India // J Clin Diagn Res. – 2015. - №9(1). – P. 1-3.
- 11 Fiszenson-Albala F¹, Auzevie V, Mahe E, Farinotti R, Durand-Stocco C, Crickx B, Descamps V. A 6-month prospective survey of cutaneous drug reactions in a hospital setting // Br J Dermatol. – 2003. - №149(5). – P. 1018-1022.
- 12 Si Xian Wong, Mun Yee Tham, Chee Leok GoCh, Han Hui Cheong and Sui Yung Chan. Spontaneous cutaneous adverse drug reaction reports—An analysis of a 10-year dataset in Singapore // Pharmacol Res Perspect. – 2019. - №7(2). – P. 52-56.
- 13 Ruchika Nandha, Anita Gupta and Arif Hashmi. Cutaneous adverse drug reactions in a tertiary care teaching hospital: A North Indian perspective // Int J Appl Basic Med Res. – 2011. - №1(1). – P. 50-53.
- 14 Dr.Reeana Verma, Dr.Shreyansh Tiwari, Dr.CM Gupta, Dr.Nitin Verma. Cutaneous adverse drug reactions – A study of clinical patterns, causality, severity & preventability // Journal of Dental and Medical Sciences. – 2014. – Vol.13, Issue 7. – P. 102-109.
- 15 Jae-Woo Jung, Jae-Yeol Kim, In-Won Park et all. Genetic markers of severe cutaneous adverse reactions // Korean J Intern Med. – 2018. - №33(5). – P. 867-875.

УДК 616.517-039.75

Д.Е. Рысбекова, У.Т. Бейсебаева, О.В. Машкунова

*Казахский Национальный медицинский университет имени С.Д. Асфендиярова
Кафедра инфекционных болезней с курсом дерматовенерологии*

КАЧЕСТВО ЖИЗНИ ПРИ КОМОРБИДНЫХ СОСТОЯНИЯХ У БОЛЬНЫХ ПСОРИАЗОМ (ОБЗОР ЛИТЕРАТУРЫ)

В представленном обзоре литературы рассматриваются современные литературные данные о распространенности псориаза и его связи с псориатическим артритом (ПсА) и сопутствующей соматической патологией. Указаны наиболее распространенные коморбидные состояния при псориатической болезни с определением качества жизни, которое представляет собой важное условие оценки проводимой терапии и клинических исследований и позволяет осуществлять контроль лечения пациента.

Ключевые слова: псориаз, псориатический артрит, качество жизни, коморбидность

Псориаз – распространенный, хронически рецидивирующий дерматоз, характеризующийся эпидермальной гиперплазией с нарушением кератинизации, воспалительно-клеточными инфильтратами в дерме и эпидермисе на фоне иммунологических реакций, с тенденцией к развитию коморбидных состояний, распространению и утяжелению кожного процесса в течение жизни больного, приводящий к психической, социальной дезадаптации, не редко к инвалидизации. Псориаз является одной из самых актуальных и обсуждаемых

клинических проблем в дерматологии с точки зрения оценки тяжести псориатической болезни и выбора принципов лечения пациентов с тяжелыми формами дерматоза. Несмотря на многочисленные достижения в изучении природы псориаза, наличие большого арсенала средств и методов лечения, это заболевание занимает одно из лидирующих мест среди заболеваний кожи.

Распространенность псориаза в мире составляет в среднем около 2%, а общее число больных превышает 125 миллионов человек [1].